Free Newsletter
Prempro jury levies damages against Wyeth
For the third time in a row, the jury in a drug liability case has sided against pharma. Having already concluded that Wyeth's Prempro hormone replacement therapy was linked to plaintiff Cindy Barton's breast cancer, the 8-member panel awarded $3.75 million in compensatory damages.
The jury had also found that Wyeth hid evidence of the potential cancer risk, and for that it levied punitive damages. That amount is under court seal, however, pending the verdict in another Prempro case in Philadelphia. Wyeth had argued that news of punitive damages in this case could sway the jurors in the other case. That means the award will be sealed for at least a month, the Philadelphia Inquirer notes.
Now part of Pfizer, Wyeth faces some 9,000 plaintiffs claiming hormone-replacement injuries. Some 1,500 cases are pending in Philadelphia alone, the Associated Press reports. In a similar case tried in Nevada two years ago, a jury also found Wyeth at fault and awarded the three plaintiffs $135 million; the judge reduced that award to $35 million.
- get the news from the Inquirer
- see the AP story
Related Articles:
Breast cancer and Prempro revisited
Wyeth wrestles with Prempro suits
Wyeth appealing two hormone verdicts
Court dismisses lawsuit on Wyeth's Prempro
Comments
Synthetic Hormones, Pfizer-Wyeth Lose Big Court Case
A 112 million dollar punitive award indicates outrage at the "wanton and reckless†conduct by Wyeth. This is the tip of the iceberg, as another ten thousand cases are waiting for their day in court.
Women's Health Initiative Bombshell 2002
Seven years ago, massive numbers of women switched from Prempro to safer bio-identical hormones. This was the 2002 WHI study which showed that PremPro causes breast cancer. This massive shift away from synthetic Prempro reduced breast cancer rates to 10,000 fewer cases per year.
For More:
http://jeffreydach.com/2009/11/27/synthetic-hormones-pfizerwyeth-lose-big-court-case-by-jeffrey-dach-md.aspx
Jeffrey Dach MD
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: